Listed by the USPTO as BROWN, MINDY G
Tech Center 1600 • Art Units: 1634 1635 1636 1681 1682 1683 1685 1693
This examiner grants 58% of resolved cases
BROWN, MINDY G is associated with art unit 1634 and tech center 1600. The profile records 154 resolved cases, an allowance rate of 57.8%, an interview lift of 40.5%, and a median time to allowance of 996 days. The interview measure is a significant part of the profile’s prosecution signal, indicating that applicant-examiner discussion may deserve deliberate attention when written exchanges alone leave claim scope unresolved.
The listed companies are 10x Genomics Inc., ModernaTX Inc., and Wisconsin Alumni Research Foundation. The leading firms are Sheppard, Mullin, Richter & Hampton LLP, CASIMIR JONES, S.C., and CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC. These participants provide a practical reference set for counsel evaluating technology fit and representative prosecution approaches. The case volume is sufficient to make the reported rates useful as a portfolio-level planning input, while the median timeline remains relevant to filing and product-development schedules.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18404317 | SPATIAL ANALYSIS TO DETECT SEQUENCE VARIANTS | Non-Final OA | 10x Genomics, Inc. |
| 18284938 | METHODS FOR IDENTIFICATION AND RATIO DETERMINATION OF RNA SPECIES IN MULTIVALENT RNA COMPOSITIONS | Non-Final OA | ModernaTX, Inc. |
| 18612463 | HIGH THROUGHPUT NEWBORN SCREENING ASSAY FOR ANGELMAN AND PRADER-WILLI SYNDROMES | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18720587 | EXPANDED PANELS OF NUCLEIC ACID BIOMARKERS FOR PLACENTAL DYSFUNCTION | Non-Final OA | The Regents of the University of California |
| 18684274 | REPURPOSING DRUGS FOR NON-SMALL CELL LUNG CANCER | Non-Final OA | WEST VIRGINIA UNIVERSITY BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIVERSITY |
| 18465724 | TARGETED NEXT-GENERATION SEQUENCING VIA ANCHORED PRIMER EXTENSION | Non-Final OA | Roche Sequencing Solutions, Inc. |
| 18473971 | Resynthesis Kits and Methods | Non-Final OA | Illumina, Inc. |
| 18696532 | METHOD FOR PREDICTING THE RESPONSE OF A PATIENT DIAGNOSED WITH CANCER TO TREATMENT AND/OR IMAGING WITH A COMPOUND TARGETING CCK2-R, AND COMPOUND FOR USE IN METHODS OF SELECTIVELY TREATING AND/OR IMAGING CANCER | Non-Final OA | Paul Scherrer Institut |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy57.8% of resolved applications examined by Mindy G Brown were allowed (154 resolved cases), compared with 30.4% across Art Unit 1634 over the last five years.
This examiner's interview lift is +40.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Mindy G Brown took 996 days on average from filing to allowance.
Mindy G Brown examines applications in Art Unit 1634 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
